Posted inComunicati
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE Twelve-month findings showed improvement in Composite Unified Huntington's Disease Rating…









